IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma


IO Biotech Inc IOBT announced updated efficacy data and subgroup analyses from the MM1636 Phase 1/2 trial evaluating IO102-IO103 combined with Bristol Myers Squibb Co's BMY Opdivo (nivolumab) in metastatic melanoma.

  • The data showed that the three-year Overall Survival probability was 73%.
  • The median progression-free survival (mPFS) was 25.3 months. 
  • The confirmed overall response rate was 73%, with 46.7% of patients obtaining complete responses in poor prognosis patients.
  • A response rate of 81.8% (mPFS: 30.9 months) was seen in patients with elevated baseline LDH-levels; in patients classified as M1c at baseline response rate was 88.2% (mPFS: 25.6 months)
  • In a subgroup analysis, a response rate of 94.1% was observed in PD-L1+ patients (mPFS: 30.9 months) and 61.5% in PD-L1(-) patients (mPFS: 7.2 months)
  • Immune-related adverse events were comparable to those in patients receiving nivolumab monotherapy. 
  • No additional toxicity was observed in poor prognosis patients.
  • Price Action: IOBT shares are up 0.12% at $8.20 during the market session on the last check Monday.
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 1 TrialPhase 2 Trial